A 1-Year Lifestyle Intervention for Weight Loss in Individuals With Type 2 Diabetes Reduces High C-Reactive Protein Levels and Identifies Metabolic Predictors of Change: From the Look AHEAD (Action for Health in Diabetes) study by Belalcazar, L. Maria et al.
A 1-Year Lifestyle Intervention for Weight
Loss in Individuals With Type 2 Diabetes
Reduces High C-Reactive Protein Levels
and Identiﬁes Metabolic Predictors of
Change
From the Look AHEAD (Action for Health in Diabetes) study
L. MARIA BELALCAZAR, MD
1
DAVID M. REBOUSSIN, PHD
2
STEVEN M. HAFFNER, MD
3
RON C. HOOGEVEEN, PHD
3,4
ANDREA M. KRISKA, PHD
5
DAWN C. SCHWENKE, PHD
6
RUSSELL P. TRACY, PHD
7
F. XAVIER PI-SUNYER, MD
8
CHRISTIE M. BALLANTYNE, MD
3,4
FOR THE LOOK AHEAD RESEARCH GROUP*
OBJECTIVE — Weexaminedwhethera1-yearintensivelifestyleintervention(ILI)forweight
loss reduced elevated high-sensitivity C-reactive protein (hs-CRP) levels in obese individuals
with diabetes and identiﬁed metabolic and ﬁtness predictors of hs-CRP change.
RESEARCH DESIGN AND METHODS — Look AHEAD (Action for Health in Diabe-
tes) is an ongoing multicenter clinical trial examining the effects of weight loss achieved through
ILI on cardiovascular events and overall mortality in obese/overweight adults with type 2 dia-
betes.Wereporton1,759LookAHEADparticipantswhohadhs-CRPandﬁtnessdataatbaseline
and 1 year. Subjects were randomly assigned to ILI or to usual care (diabetes support and
education [DSE]). ILI involved frequent counseling to increase moderate-intensity exercise to
175 min/week, reduce caloric and saturated fat intake, and change macronutrient composition
to improve glycemic control.
RESULTS — ILI reduced median hs-CRP by 43.6% from baseline to 1 year, compared with a
16.7% reduction with DSE (P  0.001). ILI decreased weight (8.8%), A1C (0.7%), and triglyc-
erides (17%) and increased ﬁtness (19%) and HDL cholesterol (7.5%) (P  0.0001 vs. changes
with DSE). Changes in adiposity and glucose control with ILI remained independent predictors
of hs-CRP change at 1 year (P  0.0001 for each) after adjustment for demographics, smoking,
cardiovascularhistory,statinandthiazolidinedioneuse,andchangesinﬁtnessandlipidcontrol.
Neither statin nor insulin therapy modiﬁed the association between ILI and hs-CRP.
CONCLUSIONS — A 1-year lifestyle intervention for weight loss in obese individuals with
diabetes was associated with substantial reductions in hs-CRP. Improved glycemic control and
reduced adiposity had comparable effects on hs-CRP change.
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T
ype 2 diabetes is characterized by
clustered metabolic abnormalities
including hyperglycemia, elevated
triglycerides, low HDL cholesterol, and
central obesity. Elevated LDL cholesterol
is not usually observed, yet cardiovascu-
lar disease (CVD) accounts for two-thirds
of deaths in individuals with type 2 dia-
betes (1). Previous reports have shown
that levels of high-sensitivity (hs) C-reac-
tive protein (CRP) are signiﬁcantly ele-
vated in individuals with diabetes and are
associated with measures of adiposity
(2,3). Statins, which reduce hs-CRP lev-
els, are associated with decreased athero-
sclerotic disease progression and
reductions in cardiovascular events and
overall mortality (4). Although previous
studies that excluded individuals with di-
abeteshaveshownanimprovementinhs-
CRP levels with weight loss (5,6), it is
unclear whether the same beneﬁt would
be obtained in individuals with diabetes,
given the extent of their underlying met-
abolic abnormalities.
The aim of this report was to evaluate
whether lifestyle intervention for weight
loss in overweight/obese individuals with
type 2 diabetes would reduce their ele-
vated hs-CRP levels. We also investigated
the independent effects of improved gly-
cemic control and changes in adiposity,
lipids, and ﬁtness achieved with im-
proved lifestyle behaviors on hs-CRP. We
were interested in evaluating the effect of
improved glycemic control on hs-CRP
change, given that its association with in-
creased inﬂammation is less clear than
that of adiposity and in light of recent
ﬁndings that insulin-based interventions
that improve glycemic control have an
unfavorable effect on hs-CRP levels (7).
RESEARCH DESIGN AND
METHODS— We evaluated a subset
of 1,759 from 2,031 Look AHEAD (Ac-
tion for Health in Diabetes) participants
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enrollees from 15 of 16 participating
clinic sites who had hs-CRP determina-
tions and ﬁtness data at baseline and 1
year. Of the 2,031 subjects, 272 were ex-
cluded from analysis because of missing
data. Loss to follow-up at 1 year was very
low in our eligible participant pool
(3.2%),asintheoverallLookAHEADco-
hort (3.6%). The study design, methods,
and subject characteristics of Look
AHEAD, an ongoing multicenter clinical
trial examining whether a behavioral life-
style intervention targeting weight loss
will reduce cardiovascular events and
overall mortality in overweight/obese
subjects with type 2 diabetes, have been
described previously (8). In brief, sub-
jects were randomly assigned to an inten-
sivelifestyleintervention(ILI)armaiming
for a 7% weight loss from baseline or to a
diabetes, support, and education (DSE)
arm, which served as the control. ILI par-
ticipants attended frequent group and in-
dividual sessions in support of behavioral
changetoincreasemoderate-intensityex-
ercise progressively to 175 min/week, re-
duce caloric and saturated fat intake, and
changemacronutrientcompositiontoim-
prove glycemic control. DSE participants
received three group health information
sessionsduringtheyear.Participantscon-
tinued medical care with their primary
providers. Look AHEAD and this ancil-
lary study were approved by the institu-
tional review boards of the participating
centers.
Laboratory, anthropometric, and
ﬁtness determinations
A latex particle-enhanced immunoturbi-
dimetric assay (Equal Diagnostics/
Genzyme) was used to measure hs-CRP.
Intra- and interassay coefﬁcients of varia-
tion were 3.5 and 5.6%, respectively. De-
termination of ﬁtness, using submaximal
effort on a graded exercise stress test, and
procedures for obtaining anthropomet-
rics, A1C, glucose, and lipids in Look
AHEAD have been published previously
(9,10).
Statistical analysis
DescriptivestatisticsincludedmeanSD
or median and interquartile range (IQR).
hs-CRPchangesat1yearwerereportedas
median change and percent change from
baseline. Quartiles of change in BMI, ﬁt-
ness, and parameters of glucose and lipid
control were examined against change in
log hs-CRP in an exploratory approach to
evaluate linearity. The associations be-
tween changes in variables of interest and
hs-CRP change (log-transformed to cor-
rect for a nonnormal distribution) were
examinedusingmultiplelinearregression
analyses after excluding collinearity (de-
ﬁned as a correlation coefﬁcient 0.6). A
dichotomous indicator for treatment
group (ILI vs. DSE) was included in all
models to examine the signiﬁcance of
treatment effect (shown alone in model
A). Changes in each of the metabolic vari-
ables and/or ﬁtness were entered into a
separate regression model, alone (models
B–J) or in combination with other predic-
tors (models K–Q), in the presence of the
dichotomous treatment group indicator,
toevaluatetheircontributions.Allmodels
were adjusted for the effects of demo-
graphics, clinic site, history of CVD, cur-
rent smoking, and treatment with statins
and thiazolidinediones (TZDs). Treat-
ment effect (ILI) and statin and insulin
use (tested separately) were evaluated in
the full model with the use of interaction
terms to evaluate whether either pharma-
cological therapy modulated the associa-
tion of ILI with change in hs-CRP. Type I
error was ﬁxed at 0.05 for all analyses.
Analyses were performed using SAS (ver-
sion 9.2; SAS Institute, Cary, NC).
RESULTS
Baseline
Participant characteristics at baseline did
not differ by study arm (Table 1). Mean
Table 1—Baseline characteristics
ILI DSE Overall
n 923 836 1,759
Age 57.3  7.0 57.7  7.3 57.5  7.1
45–55 years 385 (41.7) 335 (40.1) 720 (40.9)
56–65 years 414 (44.9) 364 (43.5) 778 (44.2)
66–76 years 124 (13.4) 137 (16.4) 261 (14.8)
Sex
Male 378 (41.0) 342 (40.9) 720 (40.9)
Female 545 (59.0) 494 (59.1) 1,039 (59.1)
Ethnicity
White 624 (67.7) 557 (66.6) 1,181 (67.2)
African American 117 (12.7) 114 (13.6) 231 (13.1)
Hispanic 91 (9.9) 78 (9.3) 169 (9.6)
Native American 58 (6.3) 56 (6.7) 114 (6.5)
Asian/Paciﬁc Islander 8 (0.9) 8 (1.0) 16 (0.9)
Other/mixed 24 (2.6) 23 (2.8) 47 (2.7)
Duration of diabetes (years)* 6.5  6.3 6.6  6.2 6.6  6.3
History of CVD† 112 (12) 94 (11) 206 (12)
Metabolic syndrome 858 (93) 774 (93) 1,632 (93)
Current tobacco use* 34 (3.7) 21 (2.5) 55 (3.1)
Statin therapy 381 (41) 329 (39) 710 (40)
Thiazolidinedione therapy 232 (25) 225 (27) 457 (26)
Insulin therapy 138  15 117 (14) 255 (15)
Estrogen replacement* 162 (29.7) 143 (29.0) 305 (29.4)
Weight (kg) 102.0  20.2 101.0  18.6 101.5  19.5
BMI (kg/m
2) 36.3  6.3 36.0  5.9 36.2  6.1
Waist circumference (cm) 114.2  14.2 114.1  13.6 114.1  13.9
Fasting glucose (mg/dl) 153.5  44.0 157.5  48.9 155.4  46.4
A1C (%) 7.3  1.2 7.4  1.2 7.3  1.2
Total cholesterol (mg/dl) 192.2  37.0 190.8  37.9 191.6  37.5
LDL cholesterol (mg/dl) 112.9  30.7 113.2  32.4 113.0  31.5
HDL cholesterol (mg/dl) 42.8  11.3 42.8  11.5 42.8  11.4
Triglycerides (mg/dl) 188.7  130.2 179.9  121.9 184.5  126.4
Fitness (submaximal) (MET) 5.2  1.5 5.1  1.6 5.2  1.5
hs-CRP (mg/l)
Overall 4.2 (1.9–9.1) 4.2 (1.9–8.8) 4.2 (1.9–8.9)
Men 2.4 (1.3–4.9) 2.4 (1.1–4.7) 2.4 (1.2–4.7)
Women 6.3 (3.0–12.0) 6.3 (2.8–11.5) 6.3 (3.0–11.7)
Data are means  SD, n (%), or median (IQR). *By self-report. †Self-reported prior myocardial infarction,
stroke, transient ischemic attack, angioplasty/stent, coronary artery bypass graft, carotid endarterectomy,
abdominal aortic aneurysm, or heart failure.
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entary, with ﬁtness values below the 20th
percentile for age. Median hs-CRP was el-
evatedat4.2(IQR1.9–8.9)mg/landwas
markedly higher in women (6.3 [IQR
3.0–11.7] mg/l) than in men (2.4 [IQR
1.2–4.7] mg/l). Because of the change in
age eligibility criteria during the 2nd year
of recruitment in Look AHEAD, subject
characteristics in this ancillary study dif-
fer slightly from those of the remaining
participants; 12% had CVD and 40%
used statins, compared with 15 and 45%,
respectively, for the remainder of Look
AHEAD enrollees (11).
Changes in metabolic variables and
hs-CRP at 1 year
As reported for the overall Look AHEAD
sample(10),subjectsintheILIarminthis
study had signiﬁcant improvements in
glucose control and weight loss at 1 year
compared with those in the DSE arm.
A1C decreased by 0.7% with ILI and by
0.2% with DSE (P  0.001). Subjects in
the ILI arm had mean weight and BMI
reductionsof9kgand3.2kg/m
2(8.8%of
baseline),respectively,comparedwithre-
spective reductions of 0.8 kg and 0.3
kg/m
2 (0.8% of baseline) in the DSE arm
(P0.001).ILIparticipantshadagreater
improvement in ﬁtness, with a 19% in-
crease from baseline compared with a
5.9%increaseintheDSEarm(P0.001)
(Table 2). HDL cholesterol and triglycer-
ides improved with ILI compared with
DSE, but LDL cholesterol change was not
different between arms.
Median hs-CRP at 1 year dropped by
43.6% from baseline in the ILI group,
compared with a 16.7% decrease in the
DSE group (P  0.001 for difference in
median change between ILI and DSE)
(Table 2). Women, who had a higher hs-
CRP level than men at baseline, had a
greater absolute change in median hs-
CRP level with ILI at 1 year but a similar
proportional drop in hs-CRP levels com-
pared with that in men (Table 2).
Metabolic predictors of change in
hs-CRP at 1 year
Quartiles of change representing greater
improvements in adiposity, ﬁtness, and
glucose and lipid control were associated
with greater decreases in hs-CRP.
Changes in BMI and A1C (Fig. 1) are
shown, with quartile 1 representing the
greatest reduction. Pearson correlation
coefﬁcientsbetweenvariablechanges(ex-
cept between measures of adiposity and
betweenfastingglucoseandA1C)wereall
0.46.
Regression analysis, accounting for
potential differences between treatment
arms in demographics, smoking, and
TZD and statin use, among others, con-
ﬁrmed that each of the ILI-induced im-
provements in adiposity (BMI, weight,
andwaistcircumference),glucosecontrol
(A1C and fasting glucose), triglycerides,
HDL cholesterol, and ﬁtness predicted a
decrease in hs-CRP at 1 year (analyzed as
log hs-CRP, P  0.001 for all) (Table 3,
models B–J). Change in waist circumfer-
ence with ILI contributed slightly less to
hs-CRP change (R
2  0.096) than did
change in weight (R
2  0.114) or change
in BMI (R
2  0.115) with ILI. Interest-
ingly,theimprovementinglucosecontrol
with ILI contributed to hs-CRP change to
an extent similar to that for the reduction
in adiposity (R
2  0.112 and 0.100 for
fasting glucose and A1C, respectively).
Improvements in ﬁtness with ILI ex-
plained slightly less (R
2  0.086) of the
variance in hs-CRP change at 1 year than
did changes in adiposity or glucose con-
trol. Both change in HDL cholesterol and
change in triglyceride levels, but not
change in LDL cholesterol, predicted hs-
CRP change with ILI at 1 year.
Whenchangeinﬁtnesswasevaluated
in the regression model with change in
A1C (model K), we found that each pre-
dicted hs-CRP change. However, when
change in BMI was added to the model
(model L), ﬁtness was no longer a signif-
icant predictor, suggesting that the
change in adiposity associated with im-
proved ﬁtness partially explained the de-
cline in hs-CRP with ILI at 1 year. On the
other hand, when change in BMI or
change in ﬁtness was added to a model
containing HDL cholesterol (models M
and O, respectively) or triglycerides
(modelsNandP,respectively),bothlipid
variables remained signiﬁcant predictors
of hs-CRP change.
A ﬁnal model (model Q), including
changes in BMI, A1C, HDL cholesterol,
triglycerides, and ﬁtness, revealed that, of
the metabolic variables studied, only im-
provements in glucose control and adi-
posity could independently account for
the decrease in hs-CRP at 1 year (P 
0.001). The beneﬁcial effects of changes
in ﬁtness, HDL cholesterol, and triglycer-
ides on hs-CRP were weakened and no
longer statistically signiﬁcant (P  0.095,
0.106, and 0.068, respectively) when
testedinthefullmodel.Statinandinsulin
use did not modify the association of ILI
and hs-CRP when each was tested sepa-
rately with the use of an interaction term
(statin use  ILI and insulin use  ILI) in
Table 2—Changes in metabolic variables, ﬁtness, and hs-CRP at 1 year
Variable* ILI DSE P value†
n 922 836
 Weight (kg) 9.0  7.6 0.8  5.0 0.001
 BMI (kg/m
2) 3.2  2.6 0.3  1.8 0.001
 Waist circumference (cm) 7.4  7.8 0.9  6.3 0.001
 Fasting glucose (mg/dl) 21.7  44.4 6.7  46.8 0.001
 A1C (%) 0.7  1.0 0.2  0.9 0.001
 LDL cholesterol (mg/dl) 4.3  26.2 4.8  28.7 0.75
 Triglycerides (mg/dl) 32.3  114.8 12.6  94.2 0.001
 HDL cholesterol (mg/dl) 3.2  6.9 1.4  6.6 0.001
 Fitness (submaximal) (MET) 1.0  1.4 0.3  1.1 0.001
hs-CRP in overall group
1 year (mg/l) 2.4 (1.0 to 5.6) 3.5 (1.7 to 7.4)
 (%) 43.6 16.7
 (mg/l) 1.24 (3.4 to 0.1) 0.35 (2.0 to 0.8) 0.001
hs-CRP in men
1 year (mg/l) 1.4 (0.8 to 2.9) 2.2 (1.2 to 4.0)
 (%) 40.5 8.3
 (mg/l) 0.68 (1.8 to 0.1) 0.11 (1.2 to 0.7) 0.001
hs-CRP in women
1 year (mg/l) 3.3 (1.6 to 7.8) 5.0 (2.6 to 10.0)
 (%) 47.4 20.2
 (mg/l) 1.75 (4.7 to 0.3) 0.58 (2.8 to 0.8) 0.001
DataaremeansSDormedian(IQR)unlessotherwiseindicated.*Change()frombaselineto1year.†For
difference between ILI and DSE for change in variable from baseline to 1 year.
Belalcazar and Associates
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respectively).
CONCLUSIONS — This report con-
tributes information on the effects of a
1-year lifestyle intervention for weight
lossonhs-CRPinthesettingofwhatis,to
our knowledge, the largest randomized
clinicaltrialofitskindinindividualswith
type 2 diabetes. Most studies evaluating
cardiovascular risk reduction in individ-
uals with diabetes have focused on the
effects of statins and found a substantial
beneﬁt (12). Statins not only decrease
LDL cholesterol but they also have anti-
inﬂammatory activity and have been
shown to decrease cardiovascular mortal-
ity in individuals without diabetes who
have elevated hs-CRP (4). Our report
showed that in obese men and women
with type 2 diabetes, 1 year of lifestyle
intervention (in addition to usual care),
which led to an 8.8% reduction in base-
line weight and a 0.7% drop in A1C, re-
sulted in a 43.6% decrease in median hs-
CRP, whereas usual care alone, which led
to reductions of 0.8% in baseline weight
and 0.2% in A1C, resulted in a 16.7%
decrease in median hs-CRP. The im-
provementinhs-CRPachievedwithILIin
Look AHEAD is comparable to hs-CRP
reductions with statins in people without
diabetes (4).
Esposito et al. (5) were the ﬁrst to
present compelling evidence on the ben-
eﬁt of weight loss achieved with lifestyle
behavior changes on markers of inﬂam-
mation. In a 2-year interventional study
in 160 obese women without diabetes,
they reported a 14% decrease in mean
weight and a 34% decrease in median hs-
CRP from baseline (compared with de-
creases of 3 and 9%, respectively, in the
control group). In the Diabetes Preven-
tion Program (DPP), in which 1,000 of
3,000 obese participants at risk for dia-
betes were randomly assigned to a life-
style intervention arm, behavioral
changes in physical activity and diet re-
sulted in a 7.2% decrease in baseline
weightand30%decreaseinmedianhs-
CRP at 1 year; hs-CRP in the placebo
group increased by 5% in men and did
notchangeinwomen(6).Thefewstudies
that investigated the effects of weight loss
on hs-CRP in individuals with diabetes
were small, achieved minimal weight re-
ductions, and did not adjust for changes
in both ﬁtness and glucose control (13).
Our study indicates that moderate weight
loss in obese individuals with type 2 dia-
betes is associated with a substantial re-
duction in hs-CRP levels and that
decreased adiposity is an independent
predictor of hs-CRP reduction after ac-
counting for improvements in ﬁtness,
glucose, and lipid control.
Debate continues on whether ﬁtness
and weight loss have independent effects
oninﬂammation(14).Thisisofparticular
interest in the care of obese sedentary in-
dividuals with diabetes, in whom an in-
crease in physical activity may occur
without associated weight loss. Mecha-
nisms are emerging that explain how
increased ﬁtness, via associated improve-
ments in autonomic nervous system
function, may decrease macrophage
proinﬂammatorycytokineproductionin-
dependently of weight loss (15). DPP
Figure 1—Change in hs-CRP (median and IQR) at 1 year in the DSE arm vs. the ILI arm by
quartiles (Q) of change in BMI (top) and A1C (bottom). Change in hs-CRP is a proportional
change,withnumbers1.0indicatingadecreaseinhs-CRPandthose1.0anincreaseinhs-CRP
and the horizontal line representing overall mean change. Q1 denotes the greatest reduction in
BMI and A1C, respectively.
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participant self-report, and concluded
that weight loss, not physical activity, ac-
counted for the changes in hs-CRP at 1
year; however, ﬁtness was not assessed
(6). Our study showed that the moderate
improvement in ﬁtness observed with ILI
in our generally obese and sedentary par-
ticipants with type 2 diabetes was associ-
ated with a reduction in hs-CRP, but the
effects were attenuated (P  0.06) when
weight loss was taken into account. Our
ﬁndings do not exclude the possibility
that greater changes in ﬁtness could have
astrongereffectonhs-CRPchangeorthat
the same change in ﬁtness in less obese
individuals with diabetes could be associ-
ated with hs-CRP change independently
of weight loss.
The predominant role of adiposity on
the regulation of the inﬂammatory re-
sponse is not surprising. Adipose tissue is
in itself a source of CRP and a major pro-
ducerofinterleukin-6,akeystimulatorof
CRP secretion (16). In obesity, adipose
tissue contains an increased number of
resident macrophages and T cells, which
interact closely with adipocytes to modu-
late the inﬂammatory response (17,18).
It was interesting to ﬁnd that the as-
sociations between improvements in
HDL cholesterol and triglyceride levels
and the decrease in hs-CRP with ILI were
independent of improved ﬁtness, glucose
control,andweightloss.HDLisknownto
bind to adipocytes (19) and to possess
anti-inﬂammatory properties, including
an inhibitory effect on monocyte che-
moattractant protein-1 (20), an impor-
tant player in macrophage recruitment to
adipose tissue (21). Elevated levels of hs-
CRP have been found in individuals with
familial hypoalphalipoproteinemia, in
whom HDL cholesterol levels are low and
the risk of coronary disease is high (22).
Triglyceride-rich lipoproteins and nones-
teriﬁedfattyacidsaretakenupbyneutro-
phils and monocytes, with generation of
reactiveoxygenspeciesandproductionof
cytokines (23). In our study, the effects
of HDL cholesterol and triglyceride
change on hs-CRP variance were attenu-
ated and no longer signiﬁcant when both
were included in the same model (model
Q).ThePearsoncorrelationcoefﬁcientfor
change in HDL cholesterol and change in
triglycerides (0.26) suggests that this
attenuation was not the result of
collinearity.
The effects of improved glucose con-
trol with lifestyle on hs-CRP were of par-
ticular interest to us in light of the recent
Table 3—Metabolic variables as predictors of hs-CRP change with 1-year ILI using multiple
variable regression analysis
Model B coefﬁcient SE R
2 P value
Model A 0.072
ILI vs. DSE 0.395 0.040 0.0001
Model B 0.115
ILI vs. DSE 0.168 0.046 0.001
Change in BMI 0.079 0.009 0.0001
Model C 0.114
ILI vs. DSE 0.170 0.046 0.001
Change in weight 0.027 0.003 0.0001
Model D 0.096
ILI vs. DSE 0.268 0.044 0.0001
Change in waist circumference 0.019 0.003 0.0001
Model E 0.112
ILI vs. DSE 0.336 0.040 0.0001
Change in fasting glucose 0.004 0.000 0.0001
Model F 0.100
ILI vs. DSE 0.315 0.041 0.0001
Change in HbA1C 0.153 0.021 0.0001
Model G 0.083
ILI vs. DSE 0.378 0.040 0.0001
Change in triglycerides 0.001 0.000 0.0001
Model H 0.079
ILI vs. DSE 0.375 0.040 0.0001
Change in HDL cholesterol 0.011 0.000 0.001
Model I 0.072
ILI vs. DSE 0.395 0.040 0.0001
Change in LDL cholesterol 0.000 0.001 0.44
Model J 0.086
ILI vs. DSE 0.332 0.041 0.0001
Change in ﬁtness 0.085 0.017 0.0001
Model K 0.11
ILI vs. DSE 0.267 0.042 0.0001
Change in A1C 0.143 0.021 0.0001
Change in ﬁtness 0.072 0.016 0.0001
Model L 0.134
ILI vs. DSE 0.125 0.046 0.007
Change in BMI 0.063 0.009 0.0001
Change in A1C 0.121 0.021 0.0001
Change in ﬁtness 0.033 0.017 0.0599
Model M 0.134
ILI vs. DSE 0.128 0.046 0.006
Change in BMI 0.067 0.009 0.001
Change in A1C 0.119 0.021 0.001
Change in HDL cholesterol 0.006 0.003 0.029
Model N 0.135
ILI vs. DSE 0.133 0.046 0.004
Change in BMI 0.067 0.009 0.001
Change in A1C 0.115 0.211 0.001
Change in triglycerides 0.000 0.000 0.019
Model O 0.136
ILI vs. DSE 0.122 0.046 0.008
Change in BMI 0.062 0.009 0.001
Change in A1C 0.117 0.021 0.001
Change in HDL cholesterol 0.006 0.003 0.038
Change in ﬁtness 0.030 0.017 0.078
(continued on following page)
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with type 2 diabetes, in whom a 14-week
course of insulin glargine was shown to
abrogatethehs-CRPreductionseeninthe
placebo group. The mechanisms that
would explain this ﬁnding are difﬁcult to
determine, given that the effects were re-
ported to be independent of weight gain
andbecauseithasbeenpreviouslyshown
that hyperglycemia stimulates inﬂamma-
torycytokineproduction(24).Thereport
suggested that the deleterious effect of in-
sulin therapy on the inﬂammatory state
could explain the lack of beneﬁt of im-
proved glycemic control on incident car-
diovasculareventsfoundinrecentclinical
trials. Our study showed that improved
glycemic control with ILI was associated
with a reduction in hs-CRP at 1 year. The
favorable association of improved glyce-
mia and hs-CRP change was independent
ofchangesinadiposityandpersistedafter
accounting for multiple covariates, in-
cluding statin and TZD use, and was not
affected by changes in insulin therapy
with ILI (P  0.50). Our results, in agree-
ment with a previous small study in sub-
jects with diabetes (13) and with
experimental evidence linking hypergly-
cemia with increased cytokine produc-
tion, indicate that improved glucose
controlpersedoesnotworsentheinﬂam-
matory state in individuals with diabetes.
A cross-sectional observation in which
the correlation between glycemia and hs-
CRP was not signiﬁcant after adjustment
forBMI(3)seemstocontradicttherobust
effect of improved glucose control with
ILI on hs-CRP observed in our study.
However, ﬁndings between studies can-
not be compared; the former study eval-
uatedcorrelationatbaseline,whereasthis
report evaluated variable changes at 1
year.Loweringglucosewithimproveddi-
etary and physical activity behaviors, as
observedinLookAHEAD,mayreﬂectthe
disruption of the paracrine loop between
adipocytes and macrophages that pro-
motesinﬂammation,bothlocallyandsys-
temically, and insulin resistance (25).
Our report supports a substantial
beneﬁt of lifestyle intervention for weight
loss on the chronic inﬂammatory state
characteristic of diabetes and highlights
the contribution of improved glycemic
control achieved with lifestyle changes to
the reduction of elevated hs-CRP levels in
obese sedentary individuals with diabe-
tes. Follow-up of cardiovascular out-
comes in Look AHEAD will conﬁrm
whethertheimprovementinhs-CRPwith
behavioral changes in lifestyle will trans-
late into a reduction of cardiovascular
events.
Acknowledgments— Look AHEAD is spon-
soredbytheNationalInstituteofDiabetesand
Digestive and Kidney Diseases and cospon-
sored by the National Heart, Lung, and Blood
Institute, National Institute of Nursing Re-
search,OfﬁceofResearchonWomen’sHealth,
National Center on Minority Health and
Health Disparities, and Centers for Disease
Control and Prevention. Additional sources of
fundingforLookAHEADarelistedinthesup-
plemental data available in the online appen-
dix. Work by the Look AHEAD Ancillary
Study Group Obesity, Inﬂammation and
Thrombosis was supported by the National
Heart, Lung, and Blood Institute (grants HL-
090514 to C.M.B. and HL-090514-02S3 to
L.M.B.).
No potential conﬂicts of interest relevant to
this article were reported.
L.M.B. researched data, contributed to dis-
cussion, wrote the manuscript, and reviewed/
editedthemanuscript.D.M.R.,S.M.H.,R.P.T.,
F.X.P.-S., and C.M.B. researched data, con-
tributed to discussion, and reviewed/edited
the manuscript. R.C.H. researched data and
contributed to discussion. A.M.K. and D.C.S.
contributedtodiscussionandreviewed/edited
the manuscript.
Parts of this study were presented in ab-
stract form at the 69th Scientiﬁc Sessions of
the American Diabetes Association, New Or-
leans, Louisiana, 5–9 June 2009 and at the
Scientiﬁc Sessions of the American Heart As-
sociation,Orlando,Florida,14–18November
2009.
ADDENDUM— Analyses performed
after this manuscript was accepted for
publication reveal that if baseline hs-CRP
level is included as a covariate in the ﬁnal
regressionmodelevaluatingchangeinhs-
CRP at 1 year (see Model Q, Table 3),
improvedﬁtnessandimprovedHDLcho-
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for change in ﬁtness and P  0.020 for
change in HDL cholesterol). These ﬁnd-
ingshighlighttheroleofimprovedﬁtness
andHDLcholesterolontheinﬂammatory
state characteristic of type 2 diabetes.
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